Leap Therapeutics Announces Proposed Public Offering of Common Stock
Mar 22, 2018 20:05 pm UTC| Business
CAMBRIDGE, Mass., March 22, 2018 -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten...
FalconStor Software Announces Fourth Quarter and Fiscal Year 2017 Results
Mar 22, 2018 20:05 pm UTC| Business
AUSTIN, Texas, March 22, 2018 -- FalconStor Software, Inc. (OTCQB:FALC), a market leader in storage software, today announced financial results for its fourth quarter and fiscal year ended December 31, 2017. “Q4...
Kona Grill Reports Fourth Quarter and Fiscal 2017 Results
Mar 22, 2018 20:05 pm UTC| Business
SCOTTSDALE, Ariz., March 22, 2018 -- Kona Grill, Inc. (NASDAQ:KONA), an American grill and sushi bar, reported financial results for the fourth quarter and year ended December 31, 2017. Fourth Quarter 2017 Key Items...
SMART Global Holdings Reports Second Quarter Fiscal 2018 Financial Results
Mar 22, 2018 20:05 pm UTC| Business
NEWARK, Calif., March 22, 2018 -- SMART Global Holdings, Inc. (“SMART”) (NASDAQ:SGH), parent company of SMART Modular Technologies, Inc., today reported financial results for the second quarter of...
LPL Financial Reports Monthly Activity for February 2018
Mar 22, 2018 20:05 pm UTC| Business
SAN DIEGO, March 22, 2018 -- Leading retail investment advisory firm and independent broker/dealer LPL Financial LLC, a wholly owned subsidiary of LPL Financial Holdings Inc. (NASDAQ:LPLA), today released its monthly...
Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018
Mar 22, 2018 20:01 pm UTC| Business
Conference call scheduled for Friday, 23 March, at 2:00 p.m. CET / 9:00 a.m. EDT NKG2D CARs demonstrate validity of the target with the clinical activity observed in solid and hematological cancers in the THINK1...
La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States
Mar 22, 2018 20:01 pm UTC| Business
SAN DIEGO, March 22, 2018 -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017,...